Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
12.91
USD
|
-2.34%
|
|
-1.22%
|
-13.93%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
700.1
|
398.1
|
213.2
|
204.8
|
463
|
466.4
|
-
|
-
|
Enterprise Value (EV)
1 |
650.4
|
345.3
|
124.1
|
202.4
|
424.6
|
377.9
|
158.2
|
316.1
|
P/E ratio
|
-6.52
x
|
-3.05
x
|
-1.92
x
|
-1.85
x
|
-4.23
x
|
-3.59
x
|
-4.38
x
|
-6.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
38,894
x
|
33.7
x
|
4.44
x
|
3.18
x
|
5.6
x
|
4.96
x
|
3.13
x
|
1.99
x
|
EV / Revenue
|
36,133
x
|
29.3
x
|
2.58
x
|
3.14
x
|
5.13
x
|
4.02
x
|
1.06
x
|
1.35
x
|
EV / EBITDA
|
-5.96
x
|
-2.73
x
|
-1.36
x
|
-2.59
x
|
-6.56
x
|
-4.32
x
|
-1.87
x
|
-12.1
x
|
EV / FCF
|
-9,116,658
x
|
-3,223,619
x
|
-1,448,768
x
|
-2,304,689
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.89
x
|
4.07
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,980
|
22,093
|
22,420
|
23,090
|
30,866
|
36,130
|
-
|
-
|
Reference price
2 |
33.37
|
18.02
|
9.510
|
8.870
|
15.00
|
12.91
|
12.91
|
12.91
|
Announcement Date
|
3/2/20
|
3/18/21
|
3/21/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.018
|
11.8
|
48.04
|
64.36
|
82.71
|
93.99
|
149.1
|
233.9
|
EBITDA
1 |
-109.2
|
-126.3
|
-91.46
|
-78.12
|
-64.73
|
-87.45
|
-84.66
|
-26.02
|
EBIT
1 |
-109.5
|
-126.7
|
-92.29
|
-79.04
|
-65.54
|
-94.51
|
-74.29
|
-42.15
|
Operating Margin
|
-608,211.11%
|
-1,074.15%
|
-192.11%
|
-122.82%
|
-79.23%
|
-100.55%
|
-49.84%
|
-18.02%
|
Earnings before Tax (EBT)
1 |
-105.1
|
-125.1
|
-109.4
|
-108
|
-98.32
|
-128.4
|
-112.6
|
-79.35
|
Net income
1 |
-105.1
|
-128.5
|
-110.8
|
-109.2
|
-102.2
|
-128.4
|
-108.2
|
-79.35
|
Net margin
|
-584,144.44%
|
-1,088.94%
|
-230.67%
|
-169.62%
|
-123.61%
|
-136.59%
|
-72.6%
|
-33.93%
|
EPS
2 |
-5.120
|
-5.900
|
-4.960
|
-4.790
|
-3.550
|
-3.600
|
-2.948
|
-2.115
|
Free Cash Flow
|
-71.34
|
-107.1
|
-85.64
|
-87.81
|
-
|
-
|
-
|
-
|
FCF margin
|
-396,344.44%
|
-907.71%
|
-178.27%
|
-136.45%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/18/21
|
3/21/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
16.17
|
13.56
|
16.6
|
16.1
|
18.09
|
17.19
|
21.14
|
20.85
|
23.53
|
18.78
|
23.76
|
24.2
|
27.24
|
25.79
|
34.54
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.92
|
-21.96
|
-18.72
|
-18.09
|
-20.28
|
-22.04
|
-15.38
|
-13.5
|
-14.61
|
-25.74
|
-21.76
|
-23.6
|
-23.43
|
-31.04
|
-18.56
|
Operating Margin
|
-123.13%
|
-161.88%
|
-112.71%
|
-112.36%
|
-112.1%
|
-128.23%
|
-72.77%
|
-64.74%
|
-62.09%
|
-137.05%
|
-91.55%
|
-97.52%
|
-86.01%
|
-120.34%
|
-53.74%
|
Earnings before Tax (EBT)
1 |
-27.32
|
-28.07
|
-26.66
|
-25.12
|
-28.18
|
-30.19
|
-24.08
|
-21.89
|
-22.16
|
-32.23
|
-30.62
|
-32.89
|
-32.65
|
-34.69
|
-26.58
|
Net income
1 |
-28.45
|
-28.39
|
-26.69
|
-25.83
|
-28.25
|
-30.21
|
-24.14
|
-21.88
|
-26.02
|
-32.29
|
-30.62
|
-32.89
|
-32.62
|
-34.69
|
-26.58
|
Net margin
|
-175.91%
|
-209.32%
|
-160.75%
|
-160.47%
|
-156.14%
|
-175.74%
|
-114.18%
|
-104.93%
|
-110.57%
|
-171.91%
|
-128.83%
|
-135.91%
|
-119.76%
|
-134.52%
|
-76.94%
|
EPS
2 |
-1.270
|
-1.250
|
-1.180
|
-1.130
|
-1.220
|
-1.300
|
-1.030
|
-0.6800
|
-0.7200
|
-0.9700
|
-0.8650
|
-0.8950
|
-0.8775
|
-0.9033
|
-0.7667
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/21/22
|
5/10/22
|
8/11/22
|
11/10/22
|
3/16/23
|
5/11/23
|
8/10/23
|
11/14/23
|
3/14/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
49.7
|
52.9
|
89.1
|
2.43
|
38.4
|
88.5
|
308
|
150
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-71.3
|
-107
|
-85.6
|
-87.8
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-77.8%
|
-92.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-68.7%
|
-79.2%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
153
|
162.2
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
8.580
|
4.420
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.33
|
1.22
|
-
|
-
|
-
|
2
|
4
|
6
|
Capex / Sales
|
1,805.56%
|
10.3%
|
-
|
-
|
-
|
2.13%
|
2.68%
|
2.57%
|
Announcement Date
|
3/2/20
|
3/18/21
|
3/21/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
12.91
USD Average target price
38
USD Spread / Average Target +194.35% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.93% | 466M | | +9.58% | 115B | | +12.41% | 107B | | -2.59% | 21.6B | | -12.38% | 22.31B | | -5.29% | 19.19B | | -3.35% | 18.23B | | -38.57% | 17.62B | | +7.51% | 14.26B | | +35.67% | 12.37B |
Bio Therapeutic Drugs
|